Complex HeartWare left ventricular assist device infection treated with pump exchange: clinical alert for the driveline location

2021 ◽  
Author(s):  
Keitaro Domae ◽  
Koichi Toda ◽  
Daisuke Yoshioka ◽  
Shigeru Miyagawa ◽  
Yasushi Yoshikawa ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

Left Ventricular Assist Device Infection Is Associated With Increased Mortality but Is Not a Contraindication to Transplantation

Circulation ◽  
1997 ◽  
Vol 95 (4) ◽  
pp. 814-817 ◽  
Author(s):  
Mathias Herrmann ◽  
Michael Weyand ◽  
Britta Greshake ◽  
Christof von Eiff ◽  
Richard A. Proctor ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

scholarly journals Treatment of chronic left ventricular assist device infection with local application of bacteriophages

2019 ◽  
Vol 57 (5) ◽  
pp. 1003-1004 ◽  
Author(s):  
Johanna Mulzer ◽  
Andrej Trampuz ◽  
Evgenij V Potapov
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Major Complication ◽  
Left Ventricular ◽  
Antimicrobial Treatment ◽  
Local Application ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

Abstract Left ventricular assist device-associated infections represent a major complication during long-term support. Driveline exit site infections harbour the risk of ascending into the pump, causing deep-seated infections. We report on the successful treatment of a chronic recurrent left ventricular assist device pump-associated infection by the local application of bacteriophages as adjunct to standard surgical and antimicrobial treatment.

Successful left ventricular assist device re-implantation with omental covering for MDRP device infection

2016 ◽  
Vol 19 (2) ◽  
pp. 192-195 ◽  
Author(s):  
Hitoshi Inafuku ◽  
Yukio Kuniyoshi ◽  
Satoshi Yamashiro ◽  
Yuichi Totsuka ◽  
Minoru Ono
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

scholarly journals Anesthesia in Patient with Left Ventricular Assist Device Support. A Case Report.

2020 ◽  
Vol 4 (2) ◽  
pp. 716-719
Author(s):  
Saimir KUCI ◽  
Alfred IBRAHIMI ◽  
Ermal LIKAJ ◽  
Marsela GOGA ◽  
Ervin BEJKO ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Multidrug Resistant ◽  
Left Ventricular ◽  
Resistant Bacteria ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

Background; Left ventricular assist device (LVAD) implantation is not only a bridge-to-transplantation option for patients awaiting a donor's heart, but is often used as bridge-to-destination therapy in patients unsuitable for transplantation for various reasons. Device infection remains a threatening complication, which may lead to prolonged hospitalization, need to devise exchange, urgent transplantation, and even death of the patient. Infections with multidrug-resistant (MDR) organisms pose major difficulties for eradication therapy. Especially patients who are subject to continuous hospital treatments risk contamination or change of resistances spectrum. Gold standard therapy of certain organisms often fails to eradicate surface-associated colonization of implanted devices such as cardiovascular implants, while failed eradication leads to numerous complications and an increased mortality rate among the affected patients. Device infections through multidrug-resistant bacteria, such as MRSA, are often resistant even to first-line antibiotics, due to extended resistance spectrum and reduce tissue penetration in scar tissue after multiple surgical procedures. In addition, a solid biofilm on devices is often impenetrable even for suitable antibiotics because of the isolating nature of biofilms. Case presentation; A 48-year-old patient 72 kg, height 172 cm with dilated cardiomyopathy, his course was complicated by pump failure requiring LVAD HeartMate III placement 3 years (Milan Italy). The parameters of the LVAD pump were determined for the patient from the moment of the Pump speed 5300 rpm Flow 4.4 lpm was set. The patient performed moderate activity under normal conditions. The patient regularly took Coumadin to keep the recommended INR levels at the recommended target values ​​2.5. At the site of the exit of the cavity from the skin in the region of the right hypochondrium, there was an infection that for a long time was treated with various schemes with ambulatory antibiotics Conclusions; In the present case we showed that successful eradication of a chronic LVAD driveline infection was only possible when approached both surgically and conservatively. It is important to note that a good knowledge of the physiopathology of heart failure, the widest possible information on the treatment of heart failure with the help of LVAD implantation is very important in the treatment and survival of these patients.

Sign in / Sign up

Export Citation Format

Share Document